Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Pancreatic islets are the part of the pancreas that produce insulin and help control the blood sugar. This study aims to improve islet transplantation as a treatment for Type 1 Diabetes by using a new combination of immunosuppressive drugs that have been successful in treating other autoimmune diseases and in preventing kidney transplant rejection.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 1 Diabetes
Metabolic lability/instability characterized by hypoglycemia or ketoacidosis(>2 hospital admissions in the previous year), erratic glucose profiles(MAGE >120mg/dL), or disruption in lifestyle(danger to life, self or others). Reduced awareness of hypoglycemia or > 1 episode in the last 1.5 years of severe hypoglycemia.
Persistently poor glucose control (as defined by HgbA1c>10% at the end of six months of intensive management efforts with diabetes care team.
Progressive secondary complications as defined by
a new diagnosis by an ophthalmologist of proliferative retinopathy or clinically significant macular edema or therapy with photocoagulation during the last year; or
urinary albumin excretion rate >300mg/day but proteinuria <3g/day; or
symptomatic autonomic neuropathy (as defined by postural hypotension in the setting of euvolemia, gastroparesis or diarrhea attributed to diabetic neuropathy, or neuropathic bladder as diagnosed by an urologist)
Patient weighs more than 80kg or body mass index BMI>28
Patient's insulin requirement is >55 Units/day.
Current use of immunosuppressive agents.
History of malignancy within 10 years (except for adequately treated basal or squamous cell CA of the skin).
Active peptic ulcer disease.
Severe unremitting diarrhea or other GI disorders potentially interfering with the ability to absorb oral medications.
Untreated proliferative retinopathy.
Pregnancy or breastfeeding.
Female subjects not post-menopausal or surgically sterile, or not using an acceptable method or contraception.
Major ongoing psychiatric illness.
Ongoing substance abuse, drug or alcohol; or recent history of noncompliance.
Portal hypertension or history of significant liver disease.
Lymphopenia (<1000/ul) or leukopenia (<3000 total leukocytes/ul) or an absolute CD4 count <500/ul.
Presence or history of panel-reactive anti-HLA antibody >20%.
Evidence of acute EBV infection (IgM>IgG) OR no serologic evidence of previous exposure to EBV (IgG>IgM).
Serologic evidence of infection with HIV or HbsAg or HCV Ab positive.
Creatinine clearance <60ml/min/m2.
Positive lymphocytoxic cross-match using donor lymphocytes and serum